Compounded GLP-1 Receptor Agonists Remain Widely Available

WEDNESDAY, July 22, 2026 (HealthDay News) -- Despite the end of nationwide shortages of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the market for compounded GLP-1 RA alternatives remains strong, and some of these products are from pharmacies with concerning regulatory histories, according to a study published online July 17 in JAMA Health Forum.Michael J. DiStefano, Ph.D., from University of Colorado Anschutz, and colleagues characterized available compounded GLP-1 RA products offered by weight-loss clinics and medical spas, described aspects of patient care and monitoring, and identified characteristics of compounding suppliers. The analysis included 75 brick-and-mortar weight-loss clinics and medical spas offering compounded GLP-1 RAs located in West Virginia and Oklahoma, identified by a "secret shopper" approach.The researchers found that 9.3 percent of the businesses reported offering oral compounded GLP-1 RA formulations and 56.0 percent reported offering compounded GLP-1 RA products combined with B vitamins. Suppliers included 23 compounding facilities, four of which were not licensed to perform sterile compounding. One facility had received multiple warning letters from the U.S. Food and Drug Administration, and three had been subject to state-level disciplinary action."Our findings suggest this market didn't shrink after the shortages ended as many expected," DiStefano said in a statement. "Instead, it has remained remarkably robust, raising important questions about how these products are regulated and how patients can know whether they're receiving medications that meet appropriate quality standards."One author disclosed financial ties to the biopharmaceutical industry.Abstract/Full Text.Sign up for our weekly HealthDay newsletter

Compounded GLP-1 Receptor Agonists Remain Widely Available

Related Stories

Some Benefits Found for GLP-1 Receptor Agonists in Older Adults With MASLD

AAO: Association Between GLP-1 Receptor Agonists and AMD Explored

AAO: Sequential NAION Occurs Earlier With GLP-1 Receptor Agonist Exposure

ASTRO: <30 Percent With ER+ Early-Stage Breast Cancer Remain on Endocrine Therapy at Five Years